KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Common Equity: 2017-2024

Historic Common Equity for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -$60.2 million.

  • Aquestive Therapeutics' Common Equity rose 90.95% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year increase of 90.95%. This contributed to the annual value of -$60.2 million for FY2024, which is 43.51% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Common Equity stood at -$60.2 million for FY2024, which was up 43.51% from -$106.5 million recorded in FY2023.
  • Aquestive Therapeutics' Common Equity's 5-year high stood at -$48.5 million during FY2020, with a 5-year trough of -$118.6 million in FY2022.
  • For the 3-year period, Aquestive Therapeutics' Common Equity averaged around -$95.1 million, with its median value being -$106.5 million (2023).
  • As far as peak fluctuations go, Aquestive Therapeutics' Common Equity crashed by 692.18% in 2020, and later surged by 43.51% in 2024.
  • Aquestive Therapeutics' Common Equity (Yearly) stood at -$48.5 million in 2020, then slumped by 69.36% to -$82.1 million in 2021, then slumped by 44.34% to -$118.6 million in 2022, then increased by 10.18% to -$106.5 million in 2023, then spiked by 43.51% to -$60.2 million in 2024.